Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
Wei Wang(The University of Texas MD Anderson Cancer Center), Shimin Hu(The University of Texas MD Anderson Cancer Center), Joseph A. DiGiuseppe(Hartford Hospital), Jörge E. Cortes(The University of Texas MD Anderson Cancer Center), Guilin Tang(The University of Texas MD Anderson Cancer Center), Joseph D. Khoury(St. Jude Children's Research Hospital), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Zi Chen(Dartmouth College), L. Jeffrey Medeiros(The University of Texas MD Anderson Cancer Center), Sa Wang(The University of Texas MD Anderson Cancer Center), Carlos E. Bueso‐Ramos(The University of Texas MD Anderson Cancer Center)
Cited by 191
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k